BCHE and Alzheimer disease: The six medications currently approved for the treatment of AD target the accumulation of Aβ plaques with a monoclonal antibody (aducanumab/Aduhelm), prevent the breakdown of acetylcholine in the brain’s synapses by inhibiting cholinesterase (donepezil/Aricept, rivastigmine/Exelon, and galantamine/Razadine), regulate glutamate by blocking NMDA receptors (memantine/Namenda), or combine donepezil with memantine (Namzeric).